Practical and Theoretical Radiotherapy Physics Courses
Course overview
This course provides practical and theoretical education for the support of a modern radiotherapy physics service within radiotherapy.
It is aimed primarily at recently qualified radiotherapy physicists, but should also be invaluable to post-graduate students, researchers, clinical oncologists, engineers, radiographers, manufacturers’ representatives and in fact, anyone needing to deepen or update their understanding of this rapidly evolving field.
The faculty is composed of physicists, clinicians and radiographers, many of whom are internationally renowned for their expertise. Workshops and demonstrations make full use of the facilities of the Radiotherapy and Physics Departments of The Royal Marsden NHS Foundation Trust. The course content is reviewed annually to reflect changes in practice and technology.
Course details
4-8 November 2025: the course in November will be held at our Sutton Site
Course fees
The cost for one week is £800.00. For those wishing to book the complete two weeks, the cost is discounted to £1,350.
External, full-time PhD students with proof of academic registration can book the eight lecture days of both weeks for a total of £700.
For registration details you can email our course secretary.
Contacts
Further details on course content can be obtained from the course organisers:
Tel: +44 (0)20 7808 2506
Fax: +44 (0)20 7808 2522
Tel: +44 (0)20 8661 3475
Fax: +44 (0)20 8643 3812
Latest ICR News
Silencing gene may combat formation of radiation-induced scar tissue, a new study reveals
A new study suggests that silencing CXCL12, a gene involved in tissue scarring and repair, could help reduce the formation of scar tissue that can caused by radiotherapy. Ultimately, the researchers hope this approach could improve treatment outcomes for breast cancer patients undergoing radiotherapy and reconstructive surgery.
_kevin-harrington-embed.jpg?sfvrsn=cb25ea76_1 "t-vec-infected-melanoma-cells-(green)_kevin-harrington-embed")
ASCO 2025: One-time cell therapy offers long-term survival hope for patients with advanced melanoma
A one-time immunotherapy treatment using a patient’s own immune cells has shown long-lasting benefit for people with advanced melanoma, a serious form of skin cancer, according to new five-year follow-up data from a pivotal clinical trial.
ASCO 2025: Next-generation breast cancer drug targets tumours before they have a chance to grow
A powerful new drug for advanced breast cancer can be used to treat emerging tumours, months before they have a chance to grow, helping to keep patients well for longer and delaying the need for later-line therapies including chemotherapy.
Results of a global study, funded by AstraZeneca and co-led by researchers at The Institute of Cancer Research, London, The Royal Marsden NHS Foundation Trust and Institut Curie, Paris, were presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on 1 June 2025.
.jpg?sfvrsn=5e059cab_3 "turnerasco2 (1)")
ASCO 2025: New therapy improves survival in advanced breast cancer and delays need for chemotherapy
A promising new therapy can help patients with aggressive advanced breast cancer live longer and delays the need for further chemotherapy, new research has shown.
Final results of the INAVO120 study, led by an international team of researchers including scientists at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, have demonstrated the potential of the new therapy combination for targeting PIK3CA-mutated hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer – a common form of the disease.